Curemark Revenue and Competitors

Rye, NY USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Curemark's estimated annual revenue is currently $4.2M per year.(i)
  • Curemark's estimated revenue per employee is $155,000

Employee Data

  • Curemark has 27 Employees.(i)
  • Curemark grew their employee count by 13% last year.

Curemark's People

NameTitleEmail/Phone
1
Chief Staff at CuremarkReveal Email/Phone
2
VP FinanceReveal Email/Phone
3
VP Manufacturing Sciences and TechnologyReveal Email/Phone
4
SVP, Corporate Strategy & FinanceReveal Email/Phone
5
Director Clincal OperationsReveal Email/Phone
6
Senior Director OperationsReveal Email/Phone
7
Medical DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-20%N/AN/A
#2
$6.7M438%N/AN/A
#3
$34.4M222-1%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.3M2-50%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$3.6M230%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

What Is Curemark?

Curemark, LLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Curemark's pipeline includes preclinical and clinical-stage programs for the treatment of Autism, ADHD, addiction, Schizophrenia and Parkinson's disease.

keywords:N/A

N/A

Total Funding

27

Number of Employees

$4.2M

Revenue (est)

13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Curemark News

2022-04-17 - How being more flexible can benefit your life, career

Joan Fallon is the founder and CEO of Curemark, and is considered a visionary scientist who has dedicated her life's work to championing the...

2022-04-13 - Autism Spectrum Disorder Diagnostics Market Size, Scope ...

Autism Spectrum Disorder Diagnostics Market Size, Scope And Forecast | Leading Players – Pfizer, Merck, Roche, SynapDx, Curemark.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.5M307%N/A
#2
$5.5M310%N/A
#3
$5.2M320%N/A
#4
$4.1M3223%N/A
#5
$7M35-8%N/A